Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Gilbert J Burckart und 16 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, U.S. FDA, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Drug Development, Drug-Related Side Effects and Adverse Reactions, Pediatrics, Child Development. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, Food and Drug Administration (FDA).
Abstract (Originalsprache)
Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug‐related effects may be delayed or manifested differently than in adults. Pharmacovigilance data, primarily from adults, is not always predictive of the response in children. Historically, juvenile animal studies have been used for nonclinical pediatric drug safety assessments exclusively, but the reduction in animal testing is a goal of public health agencies. To address this concern, the Office of Clinical Pharmacology at the U.S. FDA and the Triangle CERSI (Center of Excellence in Regulatory Science and Innovation) convened a workshop entitled: “Pediatric Developmental Safety Assessment and New Approach Methodologies (NAMs),” attended by experts from regulatory agencies, academia, and industry. Discussions focused on three overarching topics: (i) Secondary Pharmacology Screening Tools for Assessing Pediatric Developmental Safety; (ii) Non‐clinical Tools for Pediatric Developmental Safety Assessment; and (iii) Computational and Data‐Driven Tools for Pediatric Developmental Safety. These topics were examined within the framework of the S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals and E11A Pediatric Extrapolation guidances, which promote structured, question‐based pediatric extrapolation in drug development and authorization. The workshop concluded that NAMs hold considerable promise to advance the assessment of pediatric drug developmental safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Office of Clinical Pharmacology, U.S. FDA, Silver Spring, Maryland, USA.
- Triangle Center of Excellence in Regulatory Science and Innovation, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Silver Spring, Maryland, USA.
- Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, Tennessee, USA.
- Early Clinical Development & Translational Science, Non-Clinical Safety Evaluation, Braine L'Alleud, Belgium.
- GTEx Laboratory, Data Analysis and Coordination Center, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Department of Computational Biomedicine, Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
ORCID-Profile: Gilbert J Burckart, Gelareh Abulwerdi, Christin L Daniels, Calib Choi, Rebecca Racz, Jean-Pierre Valentin, Kristin Ardlie, Nicholas Tatonetti, Susan Laffan, Marjory Moreau, Lang Li, James J Hickman, Rajanikanth Madabushi, Bhagwat Prasad, Lynne Yao, Paul B Watkins
Förderung
- FDA HHS
- Food and Drug Administration (FDA)
Zitieren
APA
Burckart, G. J., Abulwerdi, G., Daniels, C. L., Choi, C., Racz, R., Valentin, J. P., Ardlie, K., Tatonetti, N., Laffan, S., Moreau, M., Redfern, W., Li, L., Hickman, J. J., Madabushi, R., Prasad, B., Yao, L., & Watkins, P. B. (2026). Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70493
Vancouver
Burckart GJ, Abulwerdi G, Daniels CL, Choi C, Racz R, Valentin JP, et al. Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70493
BibTeX
@article{Burckart2026,
author = {Burckart, Gilbert J and Abulwerdi, Gelareh and Daniels, Christin L and Choi, Calib and Racz, Rebecca and Valentin, Jean-Pierre and Ardlie, Kristin and Tatonetti, Nicholas and Laffan, Susan and Moreau, Marjory and Redfern, Will and Li, Lang and Hickman, James J and Madabushi, Rajanikanth and Prasad, Bhagwat and Yao, Lynne and Watkins, Paul B},
title = {Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70493}
}
EUVIMED